Several studies have shown that dual-target CAR-T cell therapy has stronger anti-tumor properties, such as MLSN constructing dual-target CAR-T cells with CD40,105 FOLR1 (folate receptor 1)106 and TAG-72 and CD47 dual-target CAR-T cells,107 which were found to have stronger anti-tumor performance than single-target CAR-T cells against cells with stronger killing ability (Fig. 6A). Here, FOLR1 is linked to neoplasm.